Cargando…

Gata2 as a Crucial Regulator of Stem Cells in Adult Hematopoiesis and Acute Myeloid Leukemia

Subversion of transcription factor (TF) activity in hematopoietic stem/progenitor cells (HSPCs) leads to the development of therapy-resistant leukemic stem cells (LSCs) that drive fulminant acute myeloid leukemia (AML). Using a conditional mouse model where zinc-finger TF Gata2 was deleted specifica...

Descripción completa

Detalles Bibliográficos
Autores principales: Menendez-Gonzalez, Juan Bautista, Vukovic, Milica, Abdelfattah, Ali, Saleh, Lubaid, Almotiri, Alhomidi, Thomas, Leigh-anne, Agirre-Lizaso, Aloña, Azevedo, Aleksandra, Menezes, Ana Catarina, Tornillo, Giusy, Edkins, Sarah, Kong, Kay, Giles, Peter, Anjos-Afonso, Fernando, Tonks, Alex, Boyd, Ashleigh S., Kranc, Kamil R., Rodrigues, Neil P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700503/
https://www.ncbi.nlm.nih.gov/pubmed/31378673
http://dx.doi.org/10.1016/j.stemcr.2019.07.005
Descripción
Sumario:Subversion of transcription factor (TF) activity in hematopoietic stem/progenitor cells (HSPCs) leads to the development of therapy-resistant leukemic stem cells (LSCs) that drive fulminant acute myeloid leukemia (AML). Using a conditional mouse model where zinc-finger TF Gata2 was deleted specifically in hematopoietic cells, we show that knockout of Gata2 leads to rapid and complete cell-autonomous loss of adult hematopoietic stem cells. By using short hairpin RNAi to target GATA2, we also identify a requirement for GATA2 in human HSPCs. In Meis1a/Hoxa9-driven AML, deletion of Gata2 impedes maintenance and self-renewal of LSCs. Ablation of Gata2 enforces an LSC-specific program of enhanced apoptosis, exemplified by attenuation of anti-apoptotic factor BCL2, and re-instigation of myeloid differentiation––which is characteristically blocked in AML. Thus, GATA2 acts as a critical regulator of normal and leukemic stem cells and mediates transcriptional networks that may be exploited therapeutically to target key facets of LSC behavior in AML.